KRRO.US Korro Bio, Inc.

Healthcare Biotechnology USA Stocks
13.61 USD
Close of Nov 15, 2026
5.20 17.35
Market cap
USD 187M
P/E
-
P/B
2.12x
ROE
-84.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KRRO.US undervalued?

Graham number

The Graham number of Korro Bio, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Korro Bio, Inc. fundamental analysis

No fundamental analysis for Korro Bio, Inc. yet.

Korro Bio, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Korro Bio, Inc.

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing pr…

Full company profile